In addition, exosomal KL-6/CAPN2/SP-B displayed significantly better performance at diagnosing ILD than serum KL-6 (AUC = 0.817, 95% CI 0.753–0.882; Fig. 3C). This evidence concerns the gene SFTPB and interstitial lung disease.